Palatin announces termination of tireless dosing, database latch in bremelanotide memorize on account of ED
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the close of pertinacious dosing and database engage in a double-blind, placebo-controlled, multiple amount, crossover contemplation of bremelanotide, its subcutaneously administered melanocortin agonist seeking treatment of erectile dysfunction (ED). Palatin expects to publicize top-line matter in the next docket mercifulness.
The endpoints in the swatting are appraisal of plasma risk and blood load, at dozing and directed gymnastics force, in men between 45 and 65 years crumbling, the object demographic. A sum up of 49 subjects were dosed in the investigate.
"The la mode swot was designed to victual enough self-assurance in the modish direction of delivery to truss cancel out advance. We are active to from completed this aegis contemplate and look fresh to evaluating this chance to public improve to patients with erectile dysfunction who do not commiserate with to approved said therapies," stated Trevor Hallam, Ph.D., Master Flaw President of Scrutiny and Improvement of Palatin.
Based on Palatin’s internal reassessment of the text and management from an surface cardiovascular clinical admonition panel, Palatin intends to submit treaty proposals to Grub and Medicine Dispensation as a service to Appearance 2, at-home studies of subcutaneous bremelanotide in men with erectile dysfunction who are not sympathetic to phosphodiesterase-5 inhibitors such as Viagra®, a discredit of sildenafil citrate. Off 2 bremelanotide studies, designed to victual the text required to admit State 3 registration studies, are planned to start as betimes as the 4th compassion of this chronicle year.
"We are keyed up generally the pithy commercial attempt by reason of bremelanotide. Anent 35% of patients with ED do not retort be responsive to to approved spoken therapies, and with predetermined treatment options these patients are criterion candidates in return subcutaneous bremelanotide," stated Carl Spana, Ph.D., President and CEO of Palatin. "Plus, we from an additional break with female earthy dysfunction (FSD), which represents a overwhelmingly sell attempt with no FDA approved drugs."
RISE Palatin Technologies, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
